This content is machine translated News from dermatooncology Melanoma with or without BRAF mutation – new therapies in the pipeline Data from two phase III trials (both from the research group led by Caroline Robert, MD, Institut Gustave Roussy in Villejuif, Paris) published earlier this year highlight the rapid development…
View Post 4 min This content is machine translated ASCO Congress What is the potential of adjuvant therapy and genetic analysis? Current research desiderata on melanoma were presented at this year’s ASCO Congress. Immunotherapy is considered the basis of today’s adjuvant treatment, as radiotherapy is no longer recommended due to too…
